A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis

Trial Profile

A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs VAY 736 (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 22 Feb 2017 Status changed from discontinued to completed.
    • 14 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Jun 2014 Planned End Date changed from 1 Oct 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top